Novartis’ alpelisib was granted FDA orphan designation as a treatment of lymphatic malformations, according to a post to the agency’s website. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVS:
- Novartis’ Sandoz receives FDA approval for biosimilar Hyrimoz HCF
- Novartis terminates collaboration and license pact with Sangamo
- Novartis’ Tafinlar + Mekinist approved by FDA for pediatric patients
- Novartis’ Sandoz signs MOU to build new biologics production plant in Slovenia
- Voyager announces Novartis exercised option to license novel capsids for $25M